Filing Flows › TScan Therapeutics (TCRX) › Q2 2026 › vs Q2 2025
TScan Therapeutics (TCRX) Q2 2026 vs Q2 2025 (year over year)
TScan Therapeutics's revenue fell $2.0M (-66%) from $3.1M in Q2 2025 to $1.1M in Q2 2026.
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.1M | $3.1M | −$2.0M | -66% |
| Other income, net | $134K | $1.7M | −$1.6M | -92% |
| Net loss | $30.4M | $37.0M | −$6.6M | -18% |
| Costs & expenses | $31.5M | $41.7M | −$10.2M | -24% |
| Operating costs | $31.5M | $41.7M | −$10.2M | -24% |
| Research & development | $23.4M | $32.6M | −$9.2M | -28% |
| General & admin | $8.1M | $9.1M | −$953K | -10% |
| Operating cash sources | $30.6M | $37.2M | −$6.6M | -18% |
| Depreciation | $699K | $698K | $1K | +0.1% |
| Share-based compensation | $2.4M | $3.3M | −$916K | -28% |
| Cash used in operations | $27.5M | $33.3M | −$5.7M | -17% |
| Net loss absorbed | $30.4M | $37.0M | −$6.6M | -18% |
| Working capital & other | $232K | $286K | −$54K | -19% |
Questions
How much did TScan Therapeutics's revenue grow year over year in Q2 2026?
TScan Therapeutics's revenue fell $2.0M (-66%) from $3.1M in Q2 2025 to $1.1M in Q2 2026.